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A European law that prevents the patenting of discoveries that contravene morality is causing 
confusion when it comes to human embryonic stem cells. The ensuing debate is markedly 
different from the one in the United States, where the scope of stem cell patents and their 
licensing are under challenge.Patent lawyers in the field of biotechnol-
ogy don’t get bored. The science they 
review is constantly changing and so are 
the laws governing how new scientific 
discoveries should be evaluated. This is 
particularly true when it comes to stem 
cells—a new field with a lot of commer-
cial potential. “The situation is similar to 
the plant transformation field in the 1980s 
and 1990s,” says Erich E. Veitenheimer, 
a partner in the Washington DC office of 
Cooley Godward Kronish LLP, a law firm 
that specializes in biotechnology patent 
claims. “There is a lot of activity. Lots of 
people finding similar things, so there are 
a lot of interferences, re-examinations, 
oppositions, litigations, and eventually 
cross-licensing.”
A good example is the highly publi-
cized challenge to three foundational 
patents on primate (including human) 
embryonic stem cells granted by the US 
Patent and Trademark Office (USPTO) to 
the Wisconsin Alumni Research Founda-
tion (WARF) in 1998 and 2001. The pat-
ents were challenged by two consumer 
groups—the New York-based Public Pat-
ent Foundation and the California-based 
Foundation for Taxpayer and Consumer 
Rights—who argued that the methods 
for isolating a primate stem cell line 
were obvious based on previous work 
(“prior art”) and therefore were not pat-
entable. The concern expressed by the 
two groups was that the broad claims in 
the three patents were hindering human 
embryonic stem cell research in the US 
by requiring researchers to negotiate 
a costly license with WARF in order to 
work in this area. In October 2006, the 
USPTO agreed to re-examine the three 
WARF patents, although it could take 
years for the re-examination process to 
be concluded; for the time being the pat-
ents continue to be valid.514 Cell 132, February 22, 2008 ©2008 ElsThe European WARF Case
In Europe, the patenting of human embry-
onic stem cells has been caught up in a 
battle not over sweeping claims but over 
morality. “The main issues in the US are 
the breadth of the patents and how they 
are being licensed. The main issue in 
Europe right now is morality,” says Philip 
Webber, a biotech patent attorney with 
Frank B. Dehn & Co. in London. WARF 
applied to the European Patent Office 
(EPO) for a European patent for cell 
cultures comprising primate embryonic 
stem cells. In 2004, the EPO refused the 
application on moral grounds—because 
the invention unavoidably involves the 
use of human embryos. WARF appealed 
this decision, which is now under review 
by the Enlarged Board of Appeal, the 
highest level for resolving such disputes 
within the EPO.
“The European Patent Office has 
to decide whether human stem cell-
based inventions are immoral or not,” 
says Webber. “The decision will include 
philosophical and moral questions. But 
the EPO is a patent-granting body, not 
an adjudicator on what is moral or not. 
It is difficult to see how it will come to a 
conclusion.” Morality does not typically 
come up in patent debates. “The moral-
ity issue is not as prevalent in arguments 
over other biotech inventions,” says 
Sarah Turner, a solicitor at the London 
office of the international law firm Lovells 
LLP. “With inventions like antibodies you 
tend to argue based on more standard 
arguments against patentability, for 
example that the invention was obvious,” 
says Turner.
But debates over morality are not 
entirely new to biotech patent law in 
Europe. The most notable case was 
Harvard University’s “oncomouse”—a 
transgenic mouse highly susceptible to evier Inc.cancer, created in the early 1980s by 
Philip Leder and Timothy Stewart. The 
patent application was filed in 1985 with 
the EPO, which considered the case at 
length, at many levels, and amidst much 
debate. The EPO eventually granted 
the patent in 1992—a decision that 
was opposed by animal-rights groups, 
church organizations, and various sec-
tions of the German Green party, who 
felt that the suffering caused to the ani-
mals was immoral. But in the end, the 
patent was maintained because the EPO 
held that the application’s purpose was 
of such importance for humanity—to 
find a cure for cancer—as to outweigh 
the suffering of the animals concerned. 
And while transgenic mice raised ethical 
concerns, the debate has never been as 
heated as with human embryonic stem 
cells. “They are such an emotive sub-
ject,” says Turner.
Ongoing Controversy
The EPO has received over 160 amicus 
curiae briefs regarding its impending 
decision on the WARF appeal from third 
parties who have an opinion on the fate 
of the application, including lawyers and 
biotech industry representatives, as well 
as religious, ethical, and green groups. 
The briefs show that public opinion is 
split and issues pertaining to stem cells 
are not easily settled. “The law says you 
cannot patent uses of human embryos 
for industrial or commercial purposes. 
You could read the wording literally. But 
if you have a product and had to use 
human embryos to get it, then it is not 
clear where that falls within the law,” 
says Helen Brearley, a patent attorney 
with Elkington and Fife LLP in Kent, UK, 
adding that a decision by the EPO that 
“broadly” excludes patenting embryos 
could stifle research and innovation.
Table 1. What Is Patentable and What Is Not in the US and Europe
Nonpatentable Patentable
United States • Human-nonhuman chimeras • Isolated/purified embryonic stem (ES) cells, including human ES cells
• Methods of deriving ES cells
• Culture conditions for ES cells
• Processes for differentiating ES cells
• Genetic transformation and nuclear transfer for altering ES cells
Europe • Processes for extracting stem cells from human 
blastocysts
• Direct destruction of human embryos
• Available human ES cell lines and their use (if 
destruction of human embryos was involved)a
• Adult human stem cells and their use
• Stem cells derived from nonhuman animal embryos and their use
United Kingdom • Processes for obtaining stem cells from human 
embryos
• Human totipotent cells with the potential to  
develop into an entire human body
• Human embryonic pluripotent stem cells
aThis point is under consideration with the WARF case currently before the Enlarged Board of Appeal of the European Patent Office. (Source: Erich 
E. Veitenheimer, a partner with the Washington DC-based Cooley Godward Kronish LLP.)Most European countries have laws in 
place to regulate human embryonic stem 
cell research. Several countries, includ-
ing Belgium, Sweden, and the UK, allow 
research using surplus human embryos 
up to 14 days of age. Others have more 
restrictive laws. Countries like Austria 
and Ireland prohibit stem cell research 
entirely. Germany and Italy prohibit deri-
vation of human embryonic stem cells, 
but scientists can import these cells for 
research use.
Because of existing regulations, 
Brearley argues that there is no need for 
another layer of regulation by the EPO. 
“The Patent Office should not decide on 
morality when the issue is not a clear cut 
decision, because in the end a patent 
does not give you the right to practice the 
invention. Instead, it just prevents oth-
ers from using it,” she explains. “When 
public opinion is divided, as in the case 
of stem cells, patent exclusions should 
be construed narrowly to exclude little 
rather than a lot.”
What Is the Law?
Rules pertaining to the patentability of 
human embryonic stem cells (see Table 
1) have their origin in a Directive adopted 
by the European Union (EU) in 1998 
that “inventions shall be considered 
unpatentable where their commercial 
exploitation would be contrary to ordre 
public [public order] or morality.” The 
Directive goes on to explain that such 
inventions would include “(a) processes 
for cloning human beings; (b) processes 
for modifying the germline genetic iden-
tity of human beings; (c) uses of human embryos for industrial or commercial 
purposes; (d) processes for modifying 
the genetic identity of animals which 
are likely to cause them suffering with-
out any substantial medical benefit to 
man or animal, and also animals result-
ing from such processes.” In addition, 
the EU Directive states that “the human 
body, at any stage in its formation or 
development, including germ cells, and 
the simple discovery of one of its ele-
ments or one of its products, including 
the sequence or partial sequence of a 
human gene, cannot be patented.”
Although the EPO is independent of the 
EU, it voluntarily adopted the Directive’s 
rules in 1999. In contrast, member states 
of the EU had no choice but to implement 
the EU Directive directly into their country’s 
laws. Ironically, the Directive was meant to 
harmonize patent law in Europe and thus 
stimulate the competitiveness of the bio-
tech industry. “But it has created consid-
erable uncertainly and disruption to patent 
law,” says Aurora Plomer, a professor of 
law at the University of Sheffield, UK. Part 
of the problem is that the Directive was 
passed four months before researcher 
James Thomson at the University of Wis-
consin, Madison reported the isolation 
of human embryonic stem cells in 1998. 
“Whether the Directive would embrace 
that invention was not at the forefront of 
discussions. So it was not debated or con-
sidered,” explains Plomer. “The question 
arose after Thomson’s article came out.”
This is why lawyers are now anxiously 
awaiting a decision on the WARF case 
by the EPO’s Enlarged Board of Appeal 
so that they can have guidance. But the Cell 13decision will not bring complete clarity, 
says WARF’s intellectual property man-
ager Paulanne Chelf. “If the EPO decides 
to broadly interpret [the moral exclu-
sion], it may decide that human embry-
onic stem cells cannot be patented. 
However, if you take those cells, culture 
them with a cocktail of growth factors 
and cytokines and end up with a culture 
of a particular differentiated cell type, is 
that method patentable? You may not 
be destroying an embryo to do this, but 
using cells from an embryo that some-
one else destroyed,” she says. “And will 
cells which are ‘reprogrammed’ from 
adult cells be patentable? They do not 
come from an embryo.”
The UK Goes Its Own Way
Another caveat is that not all EU member 
states have interpreted the Directive in 
the same way. “We have obtained allow-
ance of applications in Great Britain and 
Sweden to claims which may be rejected 
ultimately in the EPO,” says Chelf. The 
UK Intellectual Property Office (UKIPO) 
will not grant patents relating to pro-
cesses of obtaining stem cells from 
human embryos or for human totipo-
tent stem cells, which have the potential 
to develop into an entire human body. 
But, in contrast to the EPO, it will grant 
patents relating to human embryonic 
pluripotent stem cells because they do 
not have the potential to develop into an 
entire human body.
“Based on the same Directive, the 
UKIPO has interpreted the rules differ-
ently. It was up to the member states 
how they were going to interpret them,” 2, February 22, 2008 ©2008 Elsevier Inc. 515
says Webber. “The UK has interpreted 
the Directive narrowly.” This difference 
in approach has had some immediate 
effects. “We have been advising clients 
who want to file in Europe to file paral-
lel patent applications with the EPO and 
with the UKIPO,” says Webber. “They 
have more of a chance of getting some-
thing granted.”
Different laws regarding patents and 
research among EU member states 
could lead to a fragmented and confus-
ing situation. “The legal reality is that 
there is diversity of regimes in Europe,” 
says Plomer. “We could potentially end 
up in a situation where research laws are 
permissive in some countries and the 
moral exclusion applied to patents has 
the effect of not allowing that research to 
be patented. This was not the intention 
of the EU legislators when the Directive 
was adopted.”
And while many worry that unduly 
restrictive patents will hinder innovation, 
the long-term effect is not clear cut. “The 
breadth of patents in the US has caused 
a great deal of discussion and concern 
about the restrictive effects of grant-
ing patents as deterring innovation and 
blocking further research,” says Jane 
Gunnison, a partner in the patent practice 
at the firm Ropes & Gray LLP in New York 
City. “On the other hand in Europe, if it 
turns out that you cannot get a patent for 
human embryonic stem cells, will lack of a 
patent hold back innovation and research 516 Cell 132, February 22, 2008 ©2008 Elsevbecause industry wants some measure of 
protection for their investments? The two 
arguments make you aware of the com-
plexity of the situation.”
From another perspective, a lack of 
human embryonic stem cell patents in 
Europe, if that turns out to be the case, 
could spur researchers and companies 
to conduct their work in Europe, where 
they would be able to work in areas that 
could infringe a patent in the US. (They 
might, however, be prohibited from 
bringing the product of such research 
back to the US, depending on the nature 
of the product.)
“People mistakenly believe that the 
patent system can be used to regulate 
activity that is of concern to the public. 
But that is not usually the case,” says 
Gunnison. “There isn’t that kind of direct 
relationship between what is patented 
and what people work on. If one wants 
to regulate activity in a technology, other 
kinds of legal and regulatory systems are 
better suited than the patent system to 
accomplish that.”
No End in Sight?
Although a definite date has not been set, 
most lawyers who talked to Cell expected 
a decision from the EPO’s Enlarged Board 
of Appeal regarding the WARF patent 
application within the year. What will the 
decision accomplish? “The decision may 
help clarify some of the confusion, but not 
all,” says Paulanne Chelf of WARF.ier Inc.As the Enlarged Board of Appeal pon-
ders the decision, scientists are finding 
new sources of material for producing 
human embryonic stem cells. In 2007, 
Shinya Yamanaka of Kyoto University 
and James Thomson’s group indepen-
dently reported a method to generate 
human embryonic stem cell-like cells 
by reprogramming adult human skin 
cells with a cocktail of transcription fac-
tors, without the need of a human egg 
or embryo. “Are the Yamanaka cells 
caught in the morality exclusion clause? 
It depends on how wide the EPO will 
want to go with the exclusions and how 
much the EPO will look at the history of 
an invention,” says Plomer. “If the appli-
cation relates to a process that includes 
the reprogramming of a cell into an 
embryonic cell and if the process goes 
through an embryo-like state, it could 
be subject to the same moral exclusion 
[as in the WARF case].”
Experts hope that the decision by 
the EPO will bring some harmony within 
Europe by providing a European-wide 
standard for ethical issues in an area in 
which the science is quickly developing. 
“If the EPO seeks to impose an inappro-
priately broad ban on human embryonic 
stem cell patents in Europe, applicants 
may still be able to secure patent protec-
tion in selected member states,” says 
Plomer. “The serious problem ahead lies 
in the lack of integration of the EPO sys-
tem within EU law.”
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